Construction and validation of a novel ten miRNA-pair based signature for the prognosis of clear cell renal cell carcinoma

被引:0
作者
Wang, Yulin [1 ,2 ,3 ]
Shen, Ziyan [1 ,2 ,4 ]
Mo, Shaocong [5 ]
Dai, Leijie [6 ]
Song, Biao [7 ]
Gu, Wenchao [8 ]
Ding, Xiaoqiang [1 ,2 ,3 ,4 ]
Zhang, Xiaoyan [1 ,2 ,3 ,4 ,9 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Nephrol, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Shanghai Med Ctr Kidney Dis, Shanghai 200032, Peoples R China
[3] Shanghai Key Lab Kidney & Blood Purificat, Shanghai 200032, Peoples R China
[4] Shanghai Inst Kidney & Dialysis, 136 Med Coll Rd, Shanghai 200032, Peoples R China
[5] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai 200040, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200032, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Dermatol, Beijing 100005, Peoples R China
[8] Gunma Univ, Dept Diagnost Radiol & Nucl Med, Grad Sch Med, Maebashi 3718511, Japan
[9] Shanghai Inst Kidney & Dialysis, 136 Med Coll Rd, Shanghai 200032, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2022年 / 25卷
关键词
miRNA-pair; ccRCC; Prognosis; Signature; Immune; Bioinformatics; CANCER; EXPRESSION; METASTASIS; MODELS; IDENTIFICATION; ENCYCLOPEDIA; MICRORNAS; DISCOVERY; CELLMINER; NOMOGRAM;
D O I
10.1016/j.tranon.2022.101519
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Clear cell renal cell carcinoma (ccRCC) is the most predominate pathological subtype of renal cell carcinoma, causing a recurrence or metastasis rate as high as 20% to 40% after operation, for which effective prognostic signature is urgently needed. Methods: The mRNA and miRNA profiles of ccRCC specimens were collected from the Cancer Genome Atlas. MiRNA-pair risk score (miPRS) for each miRNA pair was generated as a signature and validated by univariate and multivariate Cox proportional hazards regression analysis. Functional enrichment was performed, and im-mune cells infiltration, as well as tumor mutation burden (TMB), and immunophenoscore (IPS) were evaluated between high and low miPRS groups. Target gene-prediction and differentially expressed gene-analysis were performed based on databases of miRDB, miRTarBase, and TargetScan. Multivariate Cox proportional hazards regression analysis was adopted to establish the prognostic model and Kaplan-Meier survival analysis was performed. Findings: A novel 10 miRNA-pair based signature was established. Area under the time-dependent receiver operating curve proved the performance of the signature in the training, validation, and testing cohorts. Higher TMB, as well as the higher CTLA4-negative PD1-negative IPS, were discovered in high miPRS patients. A prognostic model was built based on miPRS (1 year-, 5 year-, 10 year-ROC-AUC=0.92, 0.84, 0.82, respectively). Interpretation: The model based on miPRS is a novel and valid tool for predicting the prognosis of ccRCC. Funding: This study was supported by research grants from the China National Natural Scientific Foundation (81903972, 82002018, and 82170752) and Shanghai Sailing Program (19YF1406700 and 20YF1406000).
引用
收藏
页数:16
相关论文
共 93 条
  • [11] FRMD3 gene: its role in diabetic kidney disease. A narrative review
    Buffon, Marjorie Piuco
    Sortica, Denise Alves
    Gerchman, Fernando
    Crispim, Daisy
    Canani, Luis Henrique
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [12] Epidemiology of Renal Cell Carcinoma
    Capitanio, Umberto
    Bensalah, Karim
    Bex, Axel
    Boorjian, Stephen A.
    Bray, Freddie
    Coleman, Jonathan
    Gore, John L.
    Sun, Maxine
    Wood, Christopher
    Russo, Paul
    [J]. EUROPEAN UROLOGY, 2019, 75 (01) : 74 - 84
  • [13] PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
    Chabanon, Roman M.
    Morel, Daphne
    Eychenne, Thomas
    Colmet-Daage, Leo
    Bajrami, Ilirjana
    Dorvault, Nicolas
    Garrido, Marlene
    Meisenberg, Cornelia
    Lamb, Andrew
    Ngo, Carine
    Hopkins, Suzanna R.
    Roumeliotis, Theodoros, I
    Jouny, Samuel
    Henon, Clemence
    Kawai-Kawachi, Asuka
    Astier, Clemence
    Konde, Asha
    Del Nery, Elaine
    Massard, Christophe
    Pettitt, Stephen J.
    Margueron, Raphael
    Choudhary, Jyoti S.
    Almouzni, Genevieve
    Soria, Jean-Charles
    Deutsch, Eric
    Downs, Jessica A.
    Lord, Christopher J.
    Postel-Vinay, Sophie
    [J]. CANCER RESEARCH, 2021, 81 (11) : 2888 - 2902
  • [14] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [15] Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12
  • [16] Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma
    Chen, Jiayi
    Yao, Chunlin
    Qiao, Nan
    Ge, Yangyang
    Li, Jianhua
    Lin, Yun
    Yao, Shanglong
    [J]. CANCER MEDICINE, 2021, 10 (19): : 6590 - 6609
  • [17] miRDB: an online database for prediction of functional microRNA targets
    Chen, Yuhao
    Wang, Xiaowei
    [J]. NUCLEIC ACIDS RESEARCH, 2020, 48 (D1) : D127 - D131
  • [18] Targeting the HIF2-VEGF axis in renal cell carcinoma
    Choueiri, Toni K.
    Kaelin, William G., Jr.
    [J]. NATURE MEDICINE, 2020, 26 (10) : 1519 - 1530
  • [19] Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
    Christensen, Bryce R.
    Hajja, Yasmin M.
    Koshkin, Vadim
    Barata, Pedro C.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (02)
  • [20] Staging of renal cell carcinoma: current progress and potential advances
    Delahunt, Brett
    Eble, John N.
    Samaratunga, Hemamali
    Thunders, Michelle
    Yaxley, John W.
    Egevad, Lars
    [J]. PATHOLOGY, 2021, 53 (01) : 120 - 128